Biomedical applications of nisin
- PMID: 26678028
- PMCID: PMC4866897
- DOI: 10.1111/jam.13033
Biomedical applications of nisin
Abstract
Nisin is a bacteriocin produced by a group of Gram-positive bacteria that belongs to Lactococcus and Streptococcus species. Nisin is classified as a Type A (I) lantibiotic that is synthesized from mRNA and the translated peptide contains several unusual amino acids due to post-translational modifications. Over the past few decades, nisin has been used widely as a food biopreservative. Since then, many natural and genetically modified variants of nisin have been identified and studied for their unique antimicrobial properties. Nisin is FDA approved and generally regarded as a safe peptide with recognized potential for clinical use. Over the past two decades the application of nisin has been extended to biomedical fields. Studies have reported that nisin can prevent the growth of drug-resistant bacterial strains, such as methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Enterococci and Clostridium difficile. Nisin has now been shown to have antimicrobial activity against both Gram-positive and Gram-negative disease-associated pathogens. Nisin has been reported to have anti-biofilm properties and can work synergistically in combination with conventional therapeutic drugs. In addition, like host-defence peptides, nisin may activate the adaptive immune response and have an immunomodulatory role. Increasing evidence indicates that nisin can influence the growth of tumours and exhibit selective cytotoxicity towards cancer cells. Collectively, the application of nisin has advanced beyond its role as a food biopreservative. Thus, this review will describe and compare studies on nisin and provide insight into its future biomedical applications.
Keywords: antimicrobial peptide; biofilm; cancer; infectious disease; lantibiotic; nisin; oral disease.
© 2015 The Authors. published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology.
Conflict of interest statement
Figures
Similar articles
-
Bioengineering of the model lantibiotic nisin.Bioengineered. 2015;6(4):187-92. doi: 10.1080/21655979.2015.1049781. Epub 2015 May 13. Bioengineered. 2015. PMID: 25970137 Free PMC article. Review.
-
Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens.Appl Environ Microbiol. 2018 May 31;84(12):e00052-18. doi: 10.1128/AEM.00052-18. Print 2018 Jun 15. Appl Environ Microbiol. 2018. PMID: 29625984 Free PMC article.
-
Nisin resistance in Gram-positive bacteria and approaches to circumvent resistance for successful therapeutic use.Crit Rev Microbiol. 2021 May;47(3):376-385. doi: 10.1080/1040841X.2021.1893264. Epub 2021 Mar 9. Crit Rev Microbiol. 2021. PMID: 33689548 Review.
-
Synergistic Antimicrobial Activity Between the Broad Spectrum Bacteriocin Garvicin KS and Nisin, Farnesol and Polymyxin B Against Gram-Positive and Gram-Negative Bacteria.Curr Microbiol. 2018 Mar;75(3):272-277. doi: 10.1007/s00284-017-1375-y. Epub 2017 Oct 20. Curr Microbiol. 2018. PMID: 29058043 Free PMC article.
-
A Bioengineered Nisin Derivative To Control Streptococcus uberis Biofilms.Appl Environ Microbiol. 2021 Jul 27;87(16):e0039121. doi: 10.1128/AEM.00391-21. Epub 2021 Jul 27. Appl Environ Microbiol. 2021. PMID: 34105992 Free PMC article.
Cited by
-
The Comparative Effect of Nisin and Thioridazine as Potential Anticancer Agents on Hepatocellular Carcinoma.Rep Biochem Mol Biol. 2021 Jan;9(4):452-462. doi: 10.52547/rbmb.9.4.452. Rep Biochem Mol Biol. 2021. PMID: 33969139 Free PMC article.
-
Bromelain: A Potent Phytomedicine.Cureus. 2022 Aug 11;14(8):e27876. doi: 10.7759/cureus.27876. eCollection 2022 Aug. Cureus. 2022. PMID: 36110474 Free PMC article. Review.
-
A Cell-Free Platform Based on Nisin Biosynthesis for Discovering Novel Lanthipeptides and Guiding their Overproduction In Vivo.Adv Sci (Weinh). 2020 Jul 21;7(17):2001616. doi: 10.1002/advs.202001616. eCollection 2020 Sep. Adv Sci (Weinh). 2020. PMID: 32995136 Free PMC article.
-
An oxidation resistant pediocin PA-1 derivative and penocin A display effective anti-Listeria activity in a model human gut environment.Gut Microbes. 2022 Jan-Dec;14(1):2004071. doi: 10.1080/19490976.2021.2004071. Gut Microbes. 2022. PMID: 35104196 Free PMC article.
-
Genome mining, isolation, chemical synthesis and biological evaluation of a novel lanthipeptide, tikitericin, from the extremophilic microorganism Thermogemmatispora strain T81.Chem Sci. 2018 Aug 20;9(37):7311-7317. doi: 10.1039/c8sc02170h. eCollection 2018 Oct 7. Chem Sci. 2018. PMID: 30294420 Free PMC article.
References
-
- Ahire J, Dicks L. Nisin incorporated with 2,3-dihydroxybenzoic acid in nanofibers inhibits biofilm formation by a methicillin-resistant strain of Staphylococcus aureus. Probiot Antimicrob Proteins. 2015;7(1):52–9. - PubMed
-
- Akerey B, Le Lay C, Fliss I, et al. In vitro efficacy of nisin Z against Candida albicans adhesion and transition following contact with normal human gingival cells. J Appl Microbiol. 2009;107(4):1298–1307. - PubMed
-
- Alifax R, Chevalier R. Study of the nisinase produced by Streptococcus thermophilus. J Dairy Res. 1962;29:233–240.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
